Document is current
Any future updates will be listed below
-
Authors
Tiwaskar, Mangesh
Hwu, Chii-Min
Lim, Marcelo
Bhandary, Apeksha
Chang, Iris
-
Funding
Funding for this research was provided by:
AstraZeneca Pharma India Limited
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 6 June 2025
First Online: 21 July 2025
Declarations
:
: Dr Mangesh Tiwaskar: Nothing to disclose. Dr Chii-Min Hwu: Received manuscript development funding for the current study from AstraZeneca, grant support from Sanofi, Eli Lilly, MSD, consulting fees from Novo Nordisk, honoraria and speaker bureau fees from Eli Lilly, Sanofi, Zuellig, Amgen. Dr Marcelo Lim: Received support for medical writing from AstraZeneca. Dr Apeksha Bhandary and Dr Iris Chang are employees of AstraZeneca Pharma India Limited and AstraZeneca Pharma Taiwan Limited and may own stock and stock options.
: The study was approved by the Ethics Review Board and written informed consent was obtained from participants. We obtained approval ethics review board for all the three countries, St. Luke’s Medical Centre Institutional Ethics Review Committee for Philippines (IEC no. D1690R00082—PH 5503 IRB), Chang Gung Medical Foundation Institutional Review Board Certificate of Clinical Trial/Research Consent for Taiwan (IEC no. D1690R00082_7406_CCH), and Conscience Independent Ethics Committee review board for India (IEC no. D1690R00082).
